Changes of T lymphocyte subtypes in acute myeloid leukemia patients after auto-hematopoietic stem cell transplantation and treated with dendritic DC-CIK cells

GONG Yi,CHEN Xinghua,ZHANG Xi,ZHANG Cheng,GAO Lei,GAO L,WEN Qin,KONG Peiyan,LIU Hong,PENG Xiangui
2012-01-01
Abstract:Objective To observe the changes of T lymphocyte subtypes in acute myeloid leukemia patients after auto-hematopoietic stem cell transplantation(Auto-HSCT) and infusion of dendritic cells pulsed with frozen–thawed auto-leukemia cell lysates in combination with cytokine-induced killer cells(DC-CIK).Methods Fifty patients with acute myeloid leukemia were included in this clinical research.Before transplantation,bone marrow cells were collected for preparation of frozen–thawed auto-leukemia cell lysates,and mononuclear cells were collected during harvesting of peripheral hematopoietic stem cells.Dendritic cells were separated from mononuclear cells and pulsed with frozen–thawed auto-leukemia cell lysates and then co-cultured with mononuclear cells and cytokines to produce DC-CIK cells.Patients were infused with DC-CIK cells and IL-2 injection was given after hematopoietic reconstitution(between+30 d and +60d).Different subtypes of T lymphocytes(CD3+,CD4+,CD8+ and CD16+CD56+ T lymphocytes) were measured in these patients by flow cytometry.Results After treatment with DC-CIK cells,higher percentages of CD8+CD16+CD56+ lymphocytes were detected in patients,significantly higher than in patients without DC-CIK therapy(P<0.01).Conclusion Infusion of dendritic cells pulsed with frozen–thawed auto-leukemia cell lysates in combination with cytokine-induced killer cells(DC-CIK) can help promote CD8+ and CD16+CD56+ effector T lymphocytes,which may participate in eradicating minima residual disease(MRD) in acute myeloid leukemia after auto-hematopoietic stem cell transplantation(Auto-HSCT) and may improve progression free survival(PFS).
What problem does this paper attempt to address?